Theranostics Market Poised to Reach USD 14.45 Billion by 2033 — Precision Oncology and AI-Powered Radiopharmaceuticals Fuel an Unstoppable 14.6% CAGR Surge
Rising cancer incidence worldwide, accelerating regulatory approvals for novel radiopharmaceuticals, and the rapid integration of artificial intelligence into molecular imaging workflows are collectively supercharging market momentum. Simultaneously, growing demand for personalized medicine and companion diagnostics is pushing oncology care toward simultaneous diagnosis and targeted therapy — the very essence of theranostics. Investment surges in nuclear medicine infrastructure and isotope production are further reinforcing the commercial pipeline, making this one of the most dynamic segments in global healthcare.
HOUSTON, Texas, United States, June 2026 —
The global theranostics market is valued at USD 5.24 billion in 2025 and is forecast to climb from USD 5.93 billion in 2026 to approximately USD 14.45 billion by 2033, expanding at a CAGR of 14.6%.
The worldwide race toward precision oncology has elevated the theranostics market to a transformative position in modern medicine. Theranostics — the seamless integration of targeted diagnostic imaging with therapeutic intervention using a single radiopharmaceutical agent — has emerged as a cornerstone strategy for treating complex cancers and chronic diseases. Oncology decision-makers, hospital procurement heads, and institutional investors are actively tracking this space as it redefines treatment outcomes and reshapes pharmaceutical pipelines globally.
What Is Driving Unprecedented Market Growth?
Cancer remains the second leading cause of death worldwide, and the limitations of conventional therapy have accelerated the clinical pivot toward targeted, image-guided treatments. The theranostics market is uniquely positioned at this crossroads — combining diagnostic precision with curative intent in a single procedure.
Several structural drivers are fueling this trajectory:
Rising global prevalence of prostate, neuroendocrine, and thyroid cancers driving demand for targeted radiopharmaceutical therapies
Accelerated regulatory approvals from agencies in the U.S., EU, and Asia-Pacific for next-generation radiotracers
Expanding nuclear medicine infrastructure, particularly in emerging economies of Asia-Pacific and Latin America
Strategic pharmaceutical mergers and acquisitions focused on radiopharmaceutical pipelines
Growing reimbursement support for PSMA-targeted and DOTATATE-based theranostic procedures
Surge in clinical trial activity backed by AI-driven patient-trial matching platforms
North America — led by the United States — remains the dominant region in the theranostics market, driven by advanced imaging infrastructure, high healthcare spending, and early regulatory adoption of novel agents such as Lutetium-177 DOTATATE and Lutetium-177 PSMA-617.
Asia-Pacific is emerging as the fastest-growing region, fueled by rising cancer burden, expanding government healthcare budgets, and strategic partnerships with global radiopharmaceutical manufacturers targeting China, Japan, South Korea, and India.
🔬 Ready to explore the full growth story? Access the complete intelligence now:
Unlock Deep Market Intelligence — Request Your Free Sample Today → https://www.fortunedatavista.com/sample/1104
Segment Performance Overview
Understanding which segments are outperforming the broader market is critical for strategic planning and investment decisions within the theranostics market.
Diagnostic segment holds the largest revenue share, anchored by PET and SPECT imaging agents
Therapeutic segment is registering the fastest growth, driven by Lutetium-177 and Actinium-225 based treatments
Oncology dominates with a majority revenue share — prostate cancer and neuroendocrine tumors are the primary therapeutic targets
Neurology and cardiology applications are gaining traction as non-oncology theranostics expand
Hospitals and specialty cancer treatment centers are the highest revenue contributors
Diagnostic imaging centers are adopting AI-enabled automated scan analysis to scale theranostic procedures efficiently
PET/CT remains the gold-standard imaging modality across theranostic procedures
SPECT/CT is experiencing renewed investment following FDA clearances for advanced deep-learning reconstruction systems
AI’s Transformational Impact on the Theranostics Market
Artificial intelligence is no longer a peripheral feature — it has become a core enabler of next-generation theranostic workflows. AI algorithms are being deployed across the entire clinical pathway, fundamentally altering diagnostic precision, therapy planning, and treatment monitoring.
Key AI applications reshaping the theranostics market include automated tumor segmentation from PET/SPECT/CT scans, AI-driven quantitative tumor analysis that detects tumor heterogeneity for better therapy selection, machine learning models predicting treatment response curves and enabling precision dosing, and deep-learning image reconstruction software that reduces radiation exposure while enhancing scan quality. SNMMI’s AI-powered Global Radiopharmaceutical Trial Finder is accelerating patient-trial matching for theranostic clinical studies, expanding access globally. For pharmaceutical manufacturers, AI is shortening radiopharmaceutical development timelines and improving compound-target matching — a critical efficiency gain in a field where isotope half-lives create narrow operational windows.
Geopolitical Dynamics and Supply-Demand Analysis
The theranostics market does not operate in a vacuum — geopolitical forces are actively shaping supply chains, pricing structures, and cross-border collaboration frameworks.
Geopolitical Considerations:
Isotope supply security has become a strategic priority following supply chain disruptions experienced during the COVID-19 era and heightened by ongoing geopolitical tensions across Eastern Europe and Asia. Nations are investing in domestic cyclotron and reactor-based isotope production to reduce reliance on single-source suppliers. The United States, Canada, Netherlands, and Australia have all announced national radiopharmaceutical production initiatives to secure supply continuity for Lutetium-177, Actinium-225, and Gallium-68.
Trade policy and export controls on nuclear materials are adding regulatory complexity for multinational theranostic manufacturers operating across jurisdictions. However, bilateral cooperation agreements — particularly between the U.S. and allied nations — are creating stable corridors for cross-border isotope transfer.
Demand for theranostic procedures is significantly outpacing current radiopharmaceutical manufacturing capacity. The bottleneck lies not in clinical demand but in isotope production infrastructure and the limited number of qualified radiopharmacy compounding facilities globally. This supply gap is attracting significant capital investment from both pharma majors and private equity into isotope production networks. The long-term outlook is favorable: as manufacturing capacity scales and isotope costs decline, broader access to theranostic therapies in mid-income markets will unlock the next wave of growth.
💡 Is Your Organization Ready to Capitalize on the USD 14.45 Billion Theranostics Opportunity?
Equip your team with the most current competitive intelligence, segment forecasts, and strategic roadmap.
Buy Now → https://www.fortunedatavista.com/checkout/1104?payment_type=single
TOC Summary — Top 10 Strategic Intelligence Points
Market sizing and forecast: Detailed revenue trajectory from 2026 to 2033 across all segments and geographies, with CAGR breakdowns by region and product type
Fastest growing region: Asia-Pacific leads the growth race with expanding cancer registries and government healthcare investment, particularly in China, Japan, and South Korea
Dominant region: North America retains market leadership, commanding the largest revenue share driven by established nuclear medicine infrastructure and early product adoption
Oncology segment dominance: Prostate cancer and neuroendocrine tumor applications account for the majority of theranostic procedures and revenue, with PSMA and SSTR2 receptor targeting central to growth
AI integration analysis: Assessment of AI’s measurable impact on diagnostic accuracy, therapy planning efficiency, and clinical trial design within the theranostics ecosystem
Geopolitical risk assessment: Impact of isotope supply chain disruptions, trade restrictions, and national nuclear medicine strategies on market access and pricing
Supply-demand gap analysis: Quantified assessment of isotope manufacturing shortfalls versus rising clinical demand and projected timelines for capacity normalization
Competitive benchmarking: Profile and strategic positioning of top global players across product portfolio, pipeline depth, geographic presence, and M&A activity
Regulatory landscape: Comparative overview of FDA, EMA, and Asia-Pacific regulatory pathways for radiopharmaceutical approvals and their timelines
Investment and partnership trends: Mapping of recent high-value acquisitions, licensing deals, and co-development agreements reshaping the competitive dynamics of the theranostics market
Top Key Players Shaping the Global Theranostics Market
Novartis AG (Switzerland)
GE HealthCare Technologies Inc. (United States)
Siemens Healthineers AG (Germany)
Lantheus Holdings, Inc. (United States)
Cardinal Health, Inc. (United States)
Jubilant Pharmova Limited / Jubilant Radiopharma (India / Canada)
Point Biopharma Global Inc. (United States / Canada)
RayzeBio, Inc. (Bristol-Myers Squibb) (United States)
Fusion Pharmaceuticals Inc. (AstraZeneca) (Canada)
📊 Gain the Competitive Edge Your Strategy Team Needs in 2026
The Theranostics Market Intelligence Report — Your Blueprint for Precision Decision-Making Across North America, Europe, and Asia-Pacific
https://www.fortunedatavista.com/industry-analysis/theranostics-market
Fortune Data Vista is a premier market intelligence and consulting company based in Texas with a branch office in India. We are known for mid and assisting firms using smart actionable data. We don’t just offer surveys — we provide comprehensive strategies and professional guidance, thorough market analysis, and tailored reports to address and meet each client’s factual and holistic needs.
Our research helps businesses comprehend market dynamics, assess the viability of new investments, identify growth avenues, and comprehend the market dynamics. Each report is meticulously tailored to align and target the organizational objectives while exploring new avenues in diverse international markets.
Fortune Data Vista
Houston, Texas, United States
📞 US: +1 (917) 947–0251
📧 [email protected]
Follow Us: LinkedIn | Facebook | Twitter | YouTube
This press release is intended for business, investment, and strategy audiences seeking current intelligence on the global theranostics market.
What is Driving Growth in the Theranostics Market?
Which Region is Expected to Grow the Fastest in the Theranostics Market?
Who are the Leading Players in the Theranostics Market?
What Opportunities Exist in the Theranostics Market?
What is the Future Outlook of the Theranostics Market?
